

Number of shares and votes in Active Biotech

The number of shares and votes in Active Biotech AB (publ) has changed as a result of the recently completed rights issue.

Today, the last trading day of the month, there are in total 1,065,525,722 shares and votes in Active Biotech.

An additional 164,638,960 shares issued in the rights issue will be finally registered and admitted to trading after relevant FDI (Foreign Direct Investment) approvals have been obtained from the Inspectorate of Strategic Products.

For further information, please contact:

Helén Tuveßon, CEO, +46 46 19 21 56, helen.tuveßon@activebiotech.com
Hans Kolam, CFO, +46 46 19 20 44, hans.kolam@activebiotech.com

About Active Biotech

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that develops first-in-class immunomodulatory treatments for oncology and immunology indications with a high unmet medical need and significant commercial potential. Active Biotech currently holds three projects in its portfolio, of which tasquinimod and laquinimod are wholly owned small molecule immunomodulators with a mode of action that includes modulation of myeloid immune cell function. The projects are in clinical development for hematological malignancies and inflammatory eye disorders, respectively. The company's core focus is on the development of tasquinimod in myelofibrosis, a rare blood cancer, where clinical proof-of-concept studies has been initiated. Also ongoing is a clinical Phase Ib/IIa study in multiple myeloma. Laquinimod is in clinical development for the treatment of non-infectious uveitis. A clinical phase I program with a topical ophthalmic formulation is ongoing to support phase II development together with a partner. The third pipeline project is naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, which is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information.

This information is information that Active Biotech is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2024-12-30 08:30 CET.

Attachments

Number of shares and votes in Active Biotech